Literature DB >> 7535343

Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand.

P Engel1, N Wagner, A S Miller, T F Tedder.   

Abstract

CD22 is a B cell-restricted member of the immunoglobulin (Ig) superfamily that functions as an adhesion receptor for leukocytes and erythrocytes. CD22 is unique among members of the Ig superfamily in that it has been suggested to bind a series of sialic acid-dependent ligands, potentially through different functional domains expressed by different splice variants of CD22. In this study, the epitopes identified by a large panel of function-blocking and non-function-blocking CD22 monoclonal antibodies were localized to specific Ig-like domains, revealing that all function-blocking monoclonal antibodies bound to the first and/or second Ig-like domains. Consistent with a single ligand-binding region, the two amino-terminal domains were the functional unit that mediated CD22 adhesion with lymphocytes, neutrophils, monocytes, and erythrocytes. The predominant cell surface species of CD22 was a full length 140,000 relative molecular mass seven Ig-like domain glycoprotein and a minor 130,000 relative molecular mass form lacking the fourth domain. While the two amino-terminal Ig-like domains of CD22 are structurally similar to those found in other members of the Ig superfamily involved in cell adhesion and containing an amino acid sequence motif associated with integrin recognition, site-directed mutagenesis of critical residues surrounding this motif did not disrupt CD22-mediated adhesion. These results demonstrate that the unique ligand-binding properties of CD22 are distinct from those of other members of the Ig superfamily involved in integrin-mediated cell adhesion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535343      PMCID: PMC2191955          DOI: 10.1084/jem.181.4.1581

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  The B lymphocyte surface antigen CD75 is not an alpha-2,6-sialyltransferase but is a carbohydrate antigen, the production of which requires the enzyme.

Authors:  S Munro; B J Bast; K J Colley; T F Tedder
Journal:  Cell       Date:  1992-03-20       Impact factor: 41.582

2.  The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells.

Authors:  I Stamenkovic; D Sgroi; A Aruffo; M S Sy; T Anderson
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

3.  HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes.

Authors:  B Dörken; G Moldenhauer; A Pezzutto; R Schwartz; A Feller; S Kiesel; L M Nadler
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

4.  Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes.

Authors:  T F Tedder; G McIntyre; S F Schlossman
Journal:  Mol Immunol       Date:  1988-12       Impact factor: 4.407

5.  Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin.

Authors:  A Pezzutto; P S Rabinovitch; B Dörken; G Moldenhauer; E A Clark
Journal:  J Immunol       Date:  1988-03-15       Impact factor: 5.422

6.  Structural characterization of the human B lymphocyte-restricted differentiation antigen CD22. Comparison with CD21 (complement receptor type 2/Epstein-Barr virus receptor).

Authors:  D R Boué; T W Lebien
Journal:  J Immunol       Date:  1988-01-01       Impact factor: 5.422

7.  The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion.

Authors:  I Stamenkovic; B Seed
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

8.  The myelin-associated glycoproteins: membrane disposition, evidence of a novel disulfide linkage between immunoglobulin-like domains, and posttranslational palmitylation.

Authors:  L Pedraza; G C Owens; L A Green; J L Salzer
Journal:  J Cell Biol       Date:  1990-12       Impact factor: 10.539

9.  Residues within a conserved amino acid motif of domains 1 and 4 of VCAM-1 are required for binding to VLA-4.

Authors:  R H Vonderheide; T F Tedder; T A Springer; D E Staunton
Journal:  J Cell Biol       Date:  1994-04       Impact factor: 10.539

10.  cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions.

Authors:  G L Wilson; C H Fox; A S Fauci; J H Kehrl
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more
  22 in total

Review 1.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

2.  A reevaluation of CD22 expression in human lung cancer.

Authors:  Laurentiu M Pop; Stephen Barman; Chunli Shao; Jonathan C Poe; Guglielmo M Venturi; John M Shelton; Iliodora V Pop; David E Gerber; Luc Girard; Xiao-yun Liu; Carmen Behrens; Jaime Rodriguez-Canales; Hui Liu; Ignacio I Wistuba; James A Richardson; John D Minna; Thomas F Tedder; Ellen S Vitetta
Journal:  Cancer Res       Date:  2014-01-01       Impact factor: 12.701

3.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

Review 4.  The potential role of sialoadhesin as a macrophage recognition molecule in health and disease.

Authors:  P R Crocker; A Hartnell; J Munday; D Nath
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

Review 5.  The Sialoadhesins--a family of sialic acid-dependent cellular recognition molecules within the immunoglobulin superfamily.

Authors:  S Kelm; R Schauer; P R Crocker
Journal:  Glycoconj J       Date:  1996-12       Impact factor: 2.916

6.  Differential expression of CD22 (Lyb8) on murine B cells.

Authors:  L D Erickson; L T Tygrett; S K Bhatia; K H Grabstein; T J Waldschmidt
Journal:  Int Immunol       Date:  1996-07       Impact factor: 4.823

Review 7.  CD22: an inhibitory enigma.

Authors:  Jennifer A Walker; Kenneth G C Smith
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

8.  Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts.

Authors:  Shiloh M Martin; Robert T O'Donnell; David L Kukis; Craig K Abbey; Hayes McKnight; Julie L Sutcliffe; Joseph M Tuscano
Journal:  Mol Imaging Biol       Date:  2008-10-24       Impact factor: 3.488

9.  Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes.

Authors:  N Razi; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

10.  Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.

Authors:  Robert T O'Donnell; Yunpeng Ma; Hayes C McKnight; David Pearson; Joseph M Tuscano
Journal:  Cancer Immunol Immunother       Date:  2009-05-13       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.